Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for tough head and neck cancers

NCT ID NCT03082534

First seen Jan 29, 2026 · Last updated May 24, 2026 · Updated 12 times

Summary

This study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combo could shrink tumors or slow the disease. Patients were grouped based on whether they had tried similar drugs before. The approach aims to control the disease, not cure it, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California Los Angeles Cancer Center

    Los Angeles, California, 90095, United States

  • University of Michigan Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • Washington School of Medicine Cancer Center

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.